Q32 Bio Inc (QTTB NASDAQ) stock market data APIs
$3.339
0.25(7.5%)
as of December 5, 2025
Try our APIs with
free plan!
Q32 Bio Inc Financial Data Overview
Price chart is built with
Anychart
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti"interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb " CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition. The company was founded in 2017 and is based in Waltham, Massachusetts.
Prev. Close
3.339
Open
3.5859
High
3.6802
Low
3.1924
52 wk Range
1.345-27.61
Market Cap
44 542 K
Shares Outstanding
12 304 K
Revenue
-14 662 000
EPS
-0.6
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Q32 Bio Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Q32 Bio Inc data using free add-ons & libraries
Get Q32 Bio Inc Fundamental Data
Q32 Bio Inc Fundamental data includes:
- Net Revenue: -14 662 000
- EBITDA: -43 082 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-13
- EPS/Forecast: -1.19
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Q32 Bio Inc News
New
This Penny Biotech Stock Just Doubled on a Key Acquisition. Should You Buy Shares Here?
Q32 Bio (QTTB) shares more than doubled on Dec. 1 after the biotechnology company announced a strategic deal with the Cambridge-headquartered Akebia Therapeutics (AKBA). Q32 sold its Phase complement...
Q32 Bio Sells Complement Inhibitor ADX-097 To Akebia Therapeutics
(RTTNews) - Q32 Bio Inc. (QTTB) has sold its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics, Inc. (AKBA), securing upfront and milestone payments that will extend its cash runway into the...
Top Midday Gainers
Q32 Bio's (QTTB) shares doubled amid heavy trading after the company said Monday it sold alopecia ar PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
BC-Most Active Stocks
NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Direct Digital Holdings Inc. 23...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
